BELLWAVE-010: A phase 3 trial of nemtabrutinib and venetoclax in people with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma
This trial aims to test the medication nemtabrutinib when given with venetoclax in people with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) which has returned after (relapsed) or not responded to (refractory) treatment.
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05947851
Trial aim and background
The aim of this trial is to assess the effectiveness, safety and how well tolerated the treatment nemtabrutinib is when given in combination with venetoclax in people with relapsed or refractory CLL and SLL.
Participants in the trial will either receive nemtabrutinib and venetoclax or venetoclax and rituximab.
The trial will take involve two parts:
- Part 1: The aim is to determine a tolerated dose of nemtabrutinib.
- Part 2: The aim is to see how well nemtabrutinib plus venetoclax works in comparison to venetoclax plus rituximab.
Who can enter
Adults with CLL or SLL which has become refractory to, or has relapsed after at least one prior treatment may be eligible for this trial.
Locations
Recruitment is taking place at the following UK locations:
City Hospital, Nottingham
University College London Hospital – Cancer Clinical Trials Unit, London
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05947851
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.